EW performs slightly better than expected in Q2, looks forward to SAPIEN, mitral developments
Edwards LifeSciences Corp. reported a total revenue of $517 million for Q2, with 7.3 percent increased net sales, “driven by strong sales of transcatheter and surgical heart valves in both the U.S. and Europe,” CEO Michael Mussalem said. Combined, the two provided 16 percent of sales in the U.S., helped by the SAPIEN launch in the U.S.. […]